Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) EBT (2016 - 2026)

Mimedx's EBT history spans 16 years, with the latest figure at -$15.3 million for Q1 2026.

  • On a quarterly basis, EBT fell 278.02% to -$15.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $42.3 million, a 22.34% decrease, with the full-year FY2025 number at $66.3 million, up 15.65% from a year prior.
  • EBT hit -$15.3 million in Q1 2026 for Mimedx, down from $21.8 million in the prior quarter.
  • Over the last five years, EBT for MDXG hit a ceiling of $23.2 million in Q2 2024 and a floor of -$15.3 million in Q1 2026.
  • Historically, EBT has averaged $7.0 million across 5 years, with a median of $9.9 million in 2022.
  • The widest YoY moves for EBT: up 10732.97% in 2022, down 505.72% in 2022.
  • Tracing MDXG's EBT over 5 years: stood at $9.9 million in 2022, then surged by 41.13% to $13.9 million in 2023, then dropped by 19.15% to $11.2 million in 2024, then skyrocketed by 93.75% to $21.8 million in 2025, then tumbled by 170.34% to -$15.3 million in 2026.
  • Business Quant data shows EBT for MDXG at -$15.3 million in Q1 2026, $21.8 million in Q4 2025, and $22.8 million in Q3 2025.